Florida Cancer Specialists Aligns Leadership on Cellular Therapy, Value-Based Care
Event summary
- Florida Cancer Specialists (FCS) held its annual Clinical Summit on October 15, 2026, gathering 250 physicians and 280 advanced practice providers.
- Key discussions focused on cellular therapy, payer strategies, and expanding clinical trials to 180+ annually.
- Keynote speaker Billy Beane emphasized data-driven decision-making for high-performing teams.
- FCS operates nearly 100 locations across Florida, delivering precision oncology treatments.
The big picture
FCS's summit underscores its leadership in community oncology, where private practices increasingly compete with hospital systems through research-driven differentiation. The focus on data analytics and operational resilience reflects broader industry shifts toward value-based reimbursement models. With 180+ active trials annually, FCS positions itself as a critical access point for pre-approval therapies, a strategic advantage in Florida's competitive oncology landscape.
What we're watching
- Therapy Expansion
- How FCS will scale cellular therapy adoption across its 100+ locations.
- Payer Dynamics
- Whether evolving value-based care models sustain FCS's growth trajectory.
- Trial Acceleration
- The pace at which FCS expands early- and late-phase clinical trials.
Related topics
